Answers are grounded in this paper and cite their sources.
Adrenomedullin (ADM), a vasoactive member of the calcitonin peptide family with receptor-signalling overlap with calcitonin gene-related peptide (CGRP), has emerged as a candidate therapeutic target in migraine. Given the striking clinical parallels between migraine and persistent post-traumatic headache (PTH), we investigated whether ADM-responsive signalling contributes to migraine-like headache in adults with persistent PTH attributed to mild traumatic brain injury. We conducted a single-centre, randomised, double-blind, placebo-controlled, two-way crossover study in adults with persistent PTH and no pre-trauma history of migraine. On two experimental days separated by at least 7 days, participants received 20-minute intravenous infusions of ADM (19.9 pmol kg⁻¹ min⁻¹) and isotonic saline as the matched inactive comparator (placebo) in randomised sequence. Headache outcomes were recorded for 12 hours. The primary outcome was the within-participant incidence of experimentally induced migraine-like headache. The secondary outcome was the within-participant difference in baseline-corrected area under the curve (AUC) for headache intensity from 0 to 12 hours. Of 158 individuals assessed for eligibility, 21 were randomised, completed both periods and were analysed. Participants had a mean age of 34.3 years, 19 (90%) were female, and 18 (86%) reported a migraine-like phenotype. Migraine-like headache occurred in 17 of 21 participants (81%) after ADM and four of 21 (19%) following placebo. Fourteen participants developed migraine-like only after ADM and one only following placebo, yielding a paired absolute risk difference of 61.9 percentage points (95% CI 29.7-80.6; one-sided P < 0.001; two-sided P = 0.001). Baseline-corrected headache-intensity AUC was higher after ADM than placebo (median 1,110 [IQR 315-2205] versus 420 [-160 to 565]; P = 0.006). Median time to onset of migraine-like headache was 30 minutes after ADM and 390 minutes following placebo. Fifteen participants reported that the ADM-induced headache resembled their usual migraine-like headache episodes, and rescue medication was used by 10 participants after ADM and two after placebo. These findings identify pronounced responsiveness to ADM-linked signalling in persistent PTH and support the ADM pathway as a candidate target for mechanism-based therapeutic development, pending confirmation in independent cohorts and complementary preclinical studies.
No takes yet. Share an insight, caveat, or question.
Al‐Khazali et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: